Chief Executive Officer
Chief Financial Officer
Director of Quality Assurance and Regulatory Affairs
Director of Technical Operations and Project Management
Director of Marketing
Director of Business Development
Board Member
Board Member
Board Member
Chairman of the Board
Board Member
Board Member
Dolores Baksh, Ph.D., is a recognized leader and experienced CEO in the life sciences industry with a track record of driving innovation and growth across the cell and gene therapy (CGT) landscape. She brings deep experience in building scalable technology platforms, executing disciplined commercial strategies, and leading cross-functional teams to deliver impactful solutions from research through commercialization.
Prior to joining Applied StemCell, Dolores was Founding Partner and inaugural CEO of Hyperius Biotech, a firm dedicated to enabling CGT innovation and access. She founded Hyperius after serving as CEO of TAAV Biomanufacturing Solutions, where she championed the expansion of synthetic DNA manufacturing for AAV-based gene therapies and rapidly scaled operations and revenue growth. She has also held leadership roles at Akron Biomanufacturing, Cytiva, GE Healthcare Life Sciences, and Vineti.
Dolores holds a Ph.D. in Chemical & Biomedical Engineering from the University of Toronto and completed a postdoctoral fellowship at the NIH.
Tammy Cameron has over 20 years of experience developing and leading accounting and finance organizations in commercial, high-growth life science companies. Prior to joining ASC, Tammy served as CFO and VP Finance for companies such as Ceek Women’s Health, Intuity Medical Inc., Labcyte Inc., and Depomed. During her tenure at these organizations, she supported both private equity and debt financings and played a key role in building the internal infrastructure for commercial operations. Tammy received a B.S. in Accounting from California State University, East Bay, and is a Certified Public Accountant (inactive).
Simon Wu received his Ph.D. from Duke University in biology and has over 20 years of graduate level scientific research experience. He worked as a research scientist at Stanford University’s School of Medicine and has experience with genome editing technologies such as TALEN and CRISPR. Before joining ASC, Simon was a Senior Research Scientist at the pharmaceutical research firm Abbvie. At ASC he has embarked on a new journey to support management and lead projects to completion, and lead the technical operation team.
Matt Jenkins is a Partner at QHP Capital. Prior to joining QHP Capital, Matt established and led the private equity investment portfolio at RTI International where he focused on precision medicine, clinical research, real world evidence, genomics, population healthcare, and consumer-oriented diagnostics. Prior to that, he held various Corporate Development leadership roles in companies such as M*Modal and AllScripts. He also was a co-founder of Cellective Therapeutics, a venture investor, and a consultant at Ernst & Young.
Vern Davenport is a Partner at QHP Capital. Before joining QHP Capital, Vern was multi-time CEO, with executive and Board positions at Medfusion, CEO of Medquist (rebranded to M*Modal), Allscripts, Misys Healthcare, Kodak Health Group (now Carestream Health), Siemens, and Shared Medical Systems. Vern started his career at IBM where he spent 11 years in sales, sales leadership, and executive management positions.
Jeff Edwards is a Partner at QHP Capital. Prior to joining QHP Capital, Jeff co-managed the Principal Investment Private Equity program at the Teacher Retirement System of Texas. Jeff’s previous experience also includes M&A advisory work for Raymond James Capital Markets focusing on middle-market companies. Jeff also worked as a consultant for State Street Global Advisors. Before moving back to the Capital Markets sector, Jeff worked in finance and administrative roles in the healthcare industry with Carolinas HealthCare Systems and HCA, Inc. He started his career with the middle market investment bank RW Baird.
Heidi Hagen has extensive experience in operations management and commercializing innovative technologies for the last 30 years. Heidi’s roles have included the Chief Technology Officer of Sonoma Biotherapeutics, Interim CEO of Ziopharm Oncology, Co-Founder & CSO of Vineti, CCO of ZappRx, and numerous Board positions at therapeutics and service companies. Heidi spent ten years at both Dendreon and Immunex, holding senior operations roles at both companies.
Frank Leo is a 40-year veteran of the pharmaceutical and healthcare industries having experience with publicly traded, private equity-backed, and start-up companies in the capacity of executive, investor, and advisor. Frank served as President and Group President of Sterile Technologies and Life Sciences at Cardinal Health. At Cardinal Health he oversaw the growth of the biotechnology and life sciences group, which was later spun out to form Catalent Inc. Frank is a serial entrepreneur, having been involved in business value creation and start-ups in the medical device, sterile drug, biotechnology, and healthcare technology spaces.
Todd Garland currently serves as the President of Bruker Spatial Biology, with previous roles that include Chief Commercial Officer at NanoString Technologies, Inc. and Cytek Biosciences, Vice President and General Manager at BD Biosciences, Vice President of Sales in Procedural Solutions at CareFusion and Cardinal Health. Todd holds a BS in Accounting from California Polytechnic State University, San Luis Obispo, and an MBA in Finance and Marketing from the University of Michigan.
